A detailed history of Groupama Asset Managment transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Groupama Asset Managment holds 12,837 shares of MDGL stock, worth $4.46 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
12,837
Previous 11,874 8.11%
Holding current value
$4.46 Million
Previous $3.33 Billion 34.25%
% of portfolio
0.06%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$212.22 - $292.96 $204,367 - $282,120
963 Added 8.11%
12,837 $2.19 Billion
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $2.25 Million - $3.4 Million
11,659 Added 5422.79%
11,874 $3.33 Billion
Q1 2024

May 14, 2024

SELL
$171.37 - $283.23 $1.51 Million - $2.5 Million
-8,814 Reduced 97.62%
215 $3.02 Billion
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $1.09 Million - $2.14 Million
9,029 New
9,029 $2.09 Billion

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Groupama Asset Managment Portfolio

Follow Groupama Asset Managment and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Groupama Asset Managment, based on Form 13F filings with the SEC.

News

Stay updated on Groupama Asset Managment with notifications on news.